Funding

2020-2023
  • Du, Liqin (Principal). Molecular and therapeutic mechanisms of differentiation-inducing microRNA miR-506-3p in neuroblastoma, National Institute of Health, NCI, R15, Federal, $445639. (Submitted: June 6, 2019, Funded: September 1, 2020 – August 31, 2023). Grant.
  • Du, Liqin (Principal). Developing novel miR-506-3p analogs that induce neuroblastoma cell differentiation, Texas State University, REP Program, Texas State University, $8000. (Submitted: October 8, 2019, Funded: January 15, 2020 – December 31, 2021). Grant.
2017-2020
  • Du, Liqin (Principal), Kornienko, Alexander (Other), Houhgton, Peter (Other). Discovery of new differentiation agents for neuroblastoma therapy, National Institute of Health, NCI, R15, resubmissiom, Federal, $461574. (Funded: August 1, 2017 – July 31, 2020). Grant.
  • Du, Liqin (Principal). Determining the therapeutic potential of rooperol in neuroblastoma, Texas State University, REP Program, Texas State University, $8000. (Funded: January 1, 2017 – May 31, 2018). Grant.
2015-2017
  • Kerwin, S (Principal), Du, Liqin (Co-Principal). Hypoxis-derived treatment for advanced lung cancer, William and Ella Owens Medical Research Foundation, Research grant, Private / Foundation / Corporate, $153109. (Funded: January 1, 2016 – December 31, 2017). Grant.
  • Du, Liqin (Principal). Identifying microRNAs that induce neuroblastoma cell differentiation, Department of Defense, PRMRP, Discovery Award, Federal, $186828. (Funded: September 1, 2013 – February 28, 2017). Grant.
  • Du, Liqin (Principal). Identifying a novel oncogenic mechanism and diagnostic marker for neuroendocrine lung cancer, Peter Bradley Carlson Trust, Research Pilot Award, $30000. (Funded: January 1, 2015 – December 31, 2015). Grant.
2014-2015
  • Pertsemlidis, A (Principal), Du, Liqin (Co-Principal). Elucidating how chromosome 21 protects against neuroblastoma occurrence, Institute for Integration of Medicine and Science, UT Health SA, Pilot Project Award, Institutional (Higher Ed), $50000. (Funded: October 4, 2014 – September 30, 2015). Grant.
  • Du, Liqin (Co-invesitgator), Cichewicz, Robert, Mooberry, Susan. Identify bioactive natural products from the Great Lakes fungi for treating pediatric cancers, National Institute of Health, NIGMS, Multi-PI R01, Federal, $861335. (Funded: July 1, 2014 – June 30, 2015). Grant.
  • Pertsemlidis, A . (Principal), Du, Liqin (Co-Principal). What drives the regression in neuroblastoma? Clues from Chromosome 21, Helen Freeborn Kerr Foundation Award, Pilot Award, Private / Foundation / Corporate, $4000. (Funded: July 1, 2014 – June 30, 2015). Grant.
  • Du, Liqin (Principal). Identifying microRNAs that regulate LMO1 expression in neuroblastoma, Greehey Children’s Cancer Research Institute, Pilot Award, Institutional (Higher Ed), $8100. (Funded: August 1, 2013 – July 31, 2015). Grant.

2012-2014

  • Du, Liqin (Principal). Identifying long non-coding RNAs controlling neuroblastoma cell differentiation, Institute for Integration of Medicine and Science, UT Health SA, Pilot Project Award, Institutional (Higher Ed), $50000. (Funded: December 1, 2013 – November 30, 2014). Grant.
  • Du, Liqin (Principal). Discovery of new drugs for neuroblastoma from Texas plants, Bank of America Shelby Rae Tengg Foundation, Pilot Award, Private / Foundation / Corporate, $5000. (Funded: July 1, 2013 – June 30, 2014). Grant.
  • Du, Liqin (Principal). Pilot investigation of the role of microRNAs in regulating neuroblastoma cell differentiation, Greehey Children’s Cancer Research Institute, Pilot Award, Other, $10000. (Funded: September 1, 2012 – August 31, 2013). Grant.